Liebowitz M R, Hollander E, Schneier F, Campeas R, Hatterer J, Papp L, Fairbanks J, Sandberg D, Davies S, Stein M
Anxiety Disorders Clinic, New York State Psychiatric Institute, NY 10032.
J Clin Psychopharmacol. 1989 Dec;9(6):423-7.
The selective serotonin reuptake blocker fluoxetine was administered to 49 patients with obsessive-compulsive disorder in a 12-week open clinical trial. A minimum adequate trial of at least 8 weeks of treatment was completed by 39 patients. Response rates were 62% (24/39) of adequately treated patients and 49% (24/49) of the whole sample. These uncontrolled findings suggest that fluoxetine is of significant benefit for a substantial proportion of obsessive-compulsive disorder patients. However, controlled trials comparing fluoxetine with placebo and other active agents are needed to confirm this, as are studies aimed to delineate fluoxetine's full dose range, optimal length of treatment and relapse rate following discontinuation.
在一项为期12周的开放性临床试验中，对49名强迫症患者使用了选择性5-羟色胺再摄取阻滞剂氟西汀。39名患者完成了至少8周的最低充分疗程治疗。充分治疗患者的有效率为62%（24/39），整个样本的有效率为49%（24/49）。这些非对照研究结果表明，氟西汀对相当一部分强迫症患者有显著疗效。然而，需要进行将氟西汀与安慰剂及其他活性药物进行比较的对照试验来证实这一点，同时也需要开展旨在明确氟西汀的全剂量范围、最佳治疗时长以及停药后的复发率的研究。
